Table 4 Patients and clinicopathological features between low and high mSAS
Variables | All patients N = 115 | low mSAS < 8 83 (72.2%) | high mSAS ≥8 32 (27.8%) | p value |
|---|---|---|---|---|
Age (yr) | 63.3 (±10.8) | 63.2 (±10.8) | 63.8 (±10.9) | 0.736 |
Gender | 0.044 | |||
Male | 81 (70.4%) | 63 (75.9%) | 18 (56.3%) | |
Female | 34 (29.6%) | 20 (24.1%) | 14 (43.8%) | |
Body Mass Index (BMI) | 22.3 (±3.3) | 22.7 (±3.6) | 21.1 (±2.8) | 0.027 |
BMI ≥ 22 | 60 (52.2%) | 46 (55.4%) | 14 (43.8%) | 0.001 |
Diabetes Mellitus | 9 (7.8%) | 7 (8.4%) | 2 (6.3%) | 1 |
Smoking history | 73 (63.5%) | 58 (69.9%) | 15 (46.9%) | 0.030 |
American Society of Anesthesiologists Physical Status (ASA-PS) | 0.703 | |||
1 | 11 (9.6%) | 7 (8.4%) | 4 (12.5%) | |
2 | 94 (81.7%) | 68 (81.9%) | 26 (81.3%) | |
3 | 10 (8.7%) | 8 (9.6) | 2 (6.3%) | |
Tumor locationa | 0.097 | |||
Upper | 46 (40%) | 38 (45.8%) | 8 (25.0%) | |
Middle | 39 (33.9%) | 26 (31.3%) | 13 (40.6%) | |
Lower | 20 (17.4%) | 11 (13.3%) | 9 (28.1%) | |
Whole | 10 (8.7%) | 8 (9.6%) | 2 (6.3%) | |
ycStage | 0.302 | |||
I | 3 (2.6%) | 3 (3.6%) | 0 | |
II | 47 (40.9%) | 31 (37.3%) | 16 (50.0%) | |
III | 65 (56.5%) | 49 (59.0%) | 16 (50.0%) | |
Neoadjuvant chemotherapy regimen | 0.057 | |||
S-1b and cisplatin | 74 (64.3%) | 51 (61.4%) | 23 (71.9%) | |
S-1b and oxaliplatin | 14 (12.2%) | 8 (9.6%) | 6 (18.8%) | |
S-1b, docetaxel and cisplatin | 13 (11.3%) | 10 (12.0%) | 3 (9.4%) | |
Others | 14 (12.2%) | 14 (16.9%) | 0 | |
Surgical Procedure | 0.001 | |||
Distal gastrectomy | 29 (25.2%) | 13 (15.7%) | 16 (50.0%) | |
Total gastrectomy | 83 (72.3%) | 68 (81.9%) | 15 (46.9%) | |
Other | 3 (2.6%) | 2 (2.4%) | 1 (3.1%) | |
Operation time (min) | 337.1 (±111.1) | 365.6 (±113.5) | 263.4 (±59.8) | < 0.001 |
Surgical Apgar score | 6.25 (±1.1) | 5.77 (±1.2) | 7.50 (±0.67) | < 0.001 |
modified Surgical Apgar Score | 6.34 (±1.5) | 5.65 (±1.2) | 8.16 (±0.46) | < 0.001 |
Estimated blood loss (ml) | 711.5 (±627.0) | 898.1 (±644.3) | 227.6 (±112.9) | < 0.001 |
Lowest mean arterial pressure | 55.6 (±6.6) | 54.8 (±6.5) | 57.6 (±6.4) | 0.034 |
Lowest heart rate | 58.7 (±8.4) | 59.8 (±8.8) | 56.0 (±6.7) | 0.034 |
Extent of lymphadenectomy | 0.023 | |||
D2c | 48 (41.7%) | 31 (37.3%) | 17 (53.1%) | |
D2 + d | 40 (34.8%) | 27 (32.5%) | 13 (40.6%) | |
D3e | 27 (23.5%) | 25 (30.1%) | 2 (6.3%) | |
ypTa factor | 0.346 | |||
0 | 4 (3.5%) | 3 (3.6%) | 1 (3.1%) | |
T1a | 1 (0.9%) | 1 (1.2%) | 0 | |
T1b | 13 (11.3%) | 10 (12.0%) | 3 (9.4%) | |
T2 | 17 (14.8%) | 15 (18.1%) | 10 (31.3%) | |
T3 | 51 (44.3%) | 36 (43.4%) | 15 (46.9%) | |
T4a | 25 (21.7%) | 15 (18.1%) | 10 (31.3%) | |
T4b | 4 (3.5%) | 3 (3.6%) | 1 (3.1%) | |
ypNa factor | 0.781 | |||
0 | 39 (33.9%) | 30 (36.1%) | 9 (28.1%) | |
1 | 24 (20.9%) | 18 (21.7%) | 6 (18.8%) | |
2 | 26 (22.6%) | 19 (22.9%) | 7 (21.9%) | |
3 | 26 (22.6%) | 16 (19.3%) | 10 (31.3%) | |
M factor | 0.725 | |||
0 | 104 (90.4%) | 74 (89.2%) | 30 (93.8%) | |
1 | 11 (9.6%) | 9 (10.8%) | 2 (6.3%) | |
ypStagea | 0.392 | |||
0 | 3 (2.6%) | 3 (3.6%) | 0 | |
I | 19 (16.5%) | 16 (19.3%) | 3 (9.4%) | |
II | 37 (32.3%) | 25 (30.1%) | 12 (37.5%) | |
III | 45 (39.1%) | 30 (36.1%) | 15 (46.9%) | |
IV | 11 (9.6%) | 9 (10.8%) | 2 (6.3%) | |
postoperative complicationf ≥ IIIa | 41 (35.7%) | 35 (42.2%) | 6 (18.8%) | 0.029 |
Histological response of primary lesion | 0.673 | |||
0 | 2 (1.7%) | 2 (2.4%) | 0 | |
1a | 33 (28.7%) | 24 (28.9%) | 9 (28.1%) | |
1b | 30 (26.1%) | 22 (26.5%) | 8 (25.0%) | |
2 | 47 (40.9%) | 32 (38.6%) | 15 (46.9%) | |
3 | 3 (2.6%) | 3 (3.6%) | 0 |